Merit Medical Systems’ (MMSI) “Buy” Rating Reaffirmed at Needham & Company LLC

Merit Medical Systems (NASDAQ:MMSI)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $101.00 price objective on the medical instruments supplier’s stock. Needham & Company LLC’s target price indicates a potential upside of 48.03% from the stock’s current price.

MMSI has been the subject of several other research reports. Piper Sandler reduced their price target on shares of Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating for the company in a research report on Wednesday, February 18th. Canaccord Genuity Group increased their price objective on Merit Medical Systems from $93.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Barrington Research lifted their price target on shares of Merit Medical Systems from $106.00 to $109.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Robert W. Baird set a $108.00 price target on Merit Medical Systems in a research report on Tuesday, December 16th. Finally, BTIG Research assumed coverage on Merit Medical Systems in a research report on Friday, February 6th. They set a “buy” rating and a $107.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $101.25.

Merit Medical Systems Price Performance

MMSI stock opened at $68.23 on Wednesday. The business’s 50-day moving average is $76.02 and its two-hundred day moving average is $81.80. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.34 and a quick ratio of 2.95. Merit Medical Systems has a 1 year low of $66.34 and a 1 year high of $107.27. The firm has a market capitalization of $4.05 billion, a P/E ratio of 32.18, a P/E/G ratio of 1.99 and a beta of 0.65.

Merit Medical Systems (NASDAQ:MMSI) last posted its earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, beating the consensus estimate of $0.96 by $0.08. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.The firm had revenue of $393.94 million for the quarter, compared to analyst estimates of $390.77 million. During the same quarter in the prior year, the company posted $0.93 earnings per share. Merit Medical Systems’s revenue for the quarter was up 10.9% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Analysts anticipate that Merit Medical Systems will post 3.37 earnings per share for the current fiscal year.

Institutional Trading of Merit Medical Systems

Hedge funds and other institutional investors have recently modified their holdings of the business. Los Angeles Capital Management LLC acquired a new stake in shares of Merit Medical Systems during the fourth quarter worth approximately $25,000. Maseco LLP bought a new position in Merit Medical Systems in the fourth quarter worth about $26,000. Salomon & Ludwin LLC acquired a new position in Merit Medical Systems during the 3rd quarter valued at approximately $37,000. Torren Management LLC acquired a new position in shares of Merit Medical Systems during the fourth quarter valued at $38,000. Finally, Covestor Ltd grew its position in Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 336 shares during the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.